<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8886636</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">34931392</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">8886636</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1002/hbm.25752</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">HBM25752</article-id></all-ids><extracted-table><table-id>hbm25752-tbl-0001</table-id><table-label>TABLE 1</table-label><table-caption>Demographic information of enrolled participants and fast and slow progression subgroups</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="hbm25752-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Demographic information of enrolled participants and fast and slow progression subgroups</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th style="border-bottom:solid 1px #000000" align="left" colspan="2" valign="bottom" rowspan="1">ALS patients (range)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Healthy controls</th><th align="left" valign="bottom" rowspan="1" colspan="1">Statistics</th><th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">p</italic></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">N</italic> (after exclusion)</td><td colspan="2" align="left" valign="top" rowspan="1">38 (44 enrolled)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (40 enrolled)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td colspan="2" align="left" valign="top" rowspan="1">50.60 ± 8.64 (<italic toggle="yes">SD</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">51.89 ± 10.35</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">T</italic> = 0.58</td><td align="left" valign="top" rowspan="1" colspan="1">.56</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td colspan="2" align="left" valign="top" rowspan="1">15 (<italic toggle="yes">f</italic>)/23</td><td align="left" valign="top" rowspan="1" colspan="1">23 (<italic toggle="yes">f</italic>)/14</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Χ</italic><sup>2</sup> = 2.99</td><td align="left" valign="top" rowspan="1" colspan="1">.08</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALSFRS‐R</td><td colspan="2" align="left" valign="top" rowspan="1">40.89 ± 4.63 (<italic toggle="yes">SD</italic>), [29–47]</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Disease duration<xref rid="hbm25752-note-0003" ref-type="table-fn"><sup>a</sup></xref></td><td colspan="2" align="left" valign="top" rowspan="1">12 (median), 24 (75% percentile), [2–204]</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Progression rate<xref rid="hbm25752-note-0003" ref-type="table-fn"><sup>a</sup></xref></td><td colspan="2" align="left" valign="top" rowspan="1">0.41 (median), 1.03 (75% percentile), [0.1–3.75]</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UMN score</td><td colspan="2" align="left" valign="top" rowspan="1">8.94 ± 6.29 (<italic toggle="yes">SD</italic>), [0–16]</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Disease onset</td><td colspan="2" align="left" valign="top" rowspan="1">5 bulbar/33 limb</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Subgroups</td><td align="left" valign="top" rowspan="1" colspan="1">Slow progression ALS</td><td align="left" valign="top" rowspan="1" colspan="1">Fast progression ALS</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">N</italic></td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="left" valign="top" rowspan="1" colspan="1">47.43 ± 9.79 (<italic toggle="yes">SD</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">53.83 ± 10.26 (<italic toggle="yes">SD</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">T</italic> = −1.93</td><td align="left" valign="top" rowspan="1" colspan="1">.06</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (female)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (<italic toggle="yes">f</italic>)/12</td><td align="left" valign="top" rowspan="1" colspan="1">8 (<italic toggle="yes">f</italic>)/11</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Χ</italic><sup>2</sup> = .11</td><td align="left" valign="top" rowspan="1" colspan="1">.74</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALSFRS‐R</td><td align="left" valign="top" rowspan="1" colspan="1">43.32 ± 3.25 (<italic toggle="yes">SD</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">38.47 ± 4.60 (<italic toggle="yes">SD</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">T</italic> = 3.75</td><td align="left" valign="top" rowspan="1" colspan="1">.001<xref rid="hbm25752-note-0004" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Disease duration<xref rid="hbm25752-note-0003" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">22, 36 (75% percentile)</td><td align="left" valign="top" rowspan="1" colspan="1">7, 11 (75% percentile)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">T</italic> = 2.22</td><td align="left" valign="top" rowspan="1" colspan="1">.033<xref rid="hbm25752-note-0004" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Progression rate<xref rid="hbm25752-note-0003" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.25, 0.33 (75% percentile)</td><td align="left" valign="top" rowspan="1" colspan="1">1, 1.83 (75% percentile)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UMN score</td><td align="left" valign="top" rowspan="1" colspan="1">8.33 ± 6.55 (<italic toggle="yes">SD</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">9.63 ± 6.12 (<italic toggle="yes">SD</italic>)</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">T</italic> = .59</td><td align="left" valign="top" rowspan="1" colspan="1">.56</td></tr></tbody></table><table-wrap-foot id="hbm25752-ntgp-0002"><fn id="hbm25752-note-0002"><p>Abbreviation: ALSFRS‐R, ALS Functional Rating Scale‐Revised.</p></fn><fn id="hbm25752-note-0003"><label><sup>a</sup></label><p>We reported median with 75% percentile for disease duration and progression rate.</p></fn><fn id="hbm25752-note-0004"><label>*</label><p><italic toggle="yes">p</italic> values &lt;.05.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>TABLE 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic information of enrolled participants and fast and slow progression subgroups</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom"/><th style="border-bottom:solid 1px #000000" align="left" colspan="2" valign="bottom">ALS patients (range)</th><th align="left" valign="bottom">Healthy controls</th><th align="left" valign="bottom">Statistics</th><th align="left" valign="bottom">p</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top">N (after exclusion)</td><td colspan="2" align="left" valign="top">38 (44 enrolled)</td><td align="left" valign="top">37 (40 enrolled)</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Age</td><td colspan="2" align="left" valign="top">50.60 ± 8.64 (SD)</td><td align="left" valign="top">51.89 ± 10.35</td><td align="left" valign="top">T = 0.58</td><td align="left" valign="top">.56</td></tr><tr><td align="left" valign="top">Sex</td><td colspan="2" align="left" valign="top">15 (f)/23</td><td align="left" valign="top">23 (f)/14</td><td align="left" valign="top">Χ2 = 2.99</td><td align="left" valign="top">.08</td></tr><tr><td align="left" valign="top">ALSFRS‐R</td><td colspan="2" align="left" valign="top">40.89 ± 4.63 (SD), [29–47]</td><td align="left" valign="top">NA</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Disease duration???</td><td colspan="2" align="left" valign="top">12 (median), 24 (75% percentile), [2–204]</td><td align="left" valign="top">NA</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Progression rate???</td><td colspan="2" align="left" valign="top">0.41 (median), 1.03 (75% percentile), [0.1–3.75]</td><td align="left" valign="top">NA</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">UMN score</td><td colspan="2" align="left" valign="top">8.94 ± 6.29 (SD), [0–16]</td><td align="left" valign="top">NA</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Disease onset</td><td colspan="2" align="left" valign="top">5 bulbar/33 limb</td><td align="left" valign="top">NA</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Subgroups</td><td align="left" valign="top">Slow progression ALS</td><td align="left" valign="top">Fast progression ALS</td><td align="left" valign="top">NA</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">N</td><td align="left" valign="top">19</td><td align="left" valign="top">19</td><td align="left" valign="top">NA</td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Age</td><td align="left" valign="top">47.43 ± 9.79 (SD)</td><td align="left" valign="top">53.83 ± 10.26 (SD)</td><td align="left" valign="top">NA</td><td align="left" valign="top">T = −1.93</td><td align="left" valign="top">.06</td></tr><tr><td align="left" valign="top">Sex (female)</td><td align="left" valign="top">7 (f)/12</td><td align="left" valign="top">8 (f)/11</td><td align="left" valign="top">NA</td><td align="left" valign="top">Χ2 = .11</td><td align="left" valign="top">.74</td></tr><tr><td align="left" valign="top">ALSFRS‐R</td><td align="left" valign="top">43.32 ± 3.25 (SD)</td><td align="left" valign="top">38.47 ± 4.60 (SD)</td><td align="left" valign="top">NA</td><td align="left" valign="top">T = 3.75</td><td align="left" valign="top">.001???</td></tr><tr><td align="left" valign="top">Disease duration???</td><td align="left" valign="top">22, 36 (75% percentile)</td><td align="left" valign="top">7, 11 (75% percentile)</td><td align="left" valign="top">NA</td><td align="left" valign="top">T = 2.22</td><td align="left" valign="top">.033???</td></tr><tr><td align="left" valign="top">Progression rate???</td><td align="left" valign="top">0.25, 0.33 (75% percentile)</td><td align="left" valign="top">1, 1.83 (75% percentile)</td><td align="left" valign="top">NA</td><td align="left" valign="top">NA</td><td align="left" valign="top">NA</td></tr><tr><td align="left" valign="top">UMN score</td><td align="left" valign="top">8.33 ± 6.55 (SD)</td><td align="left" valign="top">9.63 ± 6.12 (SD)</td><td align="left" valign="top">NA</td><td align="left" valign="top">T = .59</td><td align="left" valign="top">.56</td></tr></tbody></table></div>Abbreviation: ALSFRS‐R, ALS Functional Rating Scale‐Revised.aWe reported median with 75% percentile for disease duration and progression rate.*p values &lt;.05.</transformed-table></extracted-table></extracted-tables-set>